Published by Josh White on 20th January 2025
(Sharecast News) - AstraZeneca announced on Monday that it has secured approval from the US Food and Drug Administration, alongside Daiichi Sankyo, for 'Datroway', or datopotamab deruxtecan, a treatment for adult patients with previously treated, unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer.